By continuing to use our site, you agree to our Terms of Use and Privacy Policy. You can learn more about how we use cookies by reviewing our Privacy Policy.

I Agree

Rick Hawkins

Rick Hawkins is currently the Chief Executive Officer of Lumos Pharma. Previously, Mr. Hawkins founded Pharmaco. As Chairman, President and Chief Executive Officer, he managed the growth of that organization to over 700 employees…Read More

John C. McKew

John McKew is President and Chief Scientific Officer of Lumos Pharma. Dr. McKew has twenty-seven years of experience developing novel therapeutics where he successfully advanced therapies through preclinical and into clinical development. Prior to Lumos Pharma, Dr. McKew served as V.P. of research at aTyr Pharma where he led a research team discovering and advancing...Read More

David B. Karpf

  David B. Karpf is Chief Medical Officer of Lumos Pharma. Dr. Karpf is an academically trained endocrinologist with over 35 years of expertise in all aspects of clinical endocrinology, including among others growth hormone deficiency, osteoporosis and metabolic bone disease, sarcopenia, as well as internal medicine.  He is also an accomplished biopharmaceutical executive. Dr....Read More

Lori Lawley

Lori Lawley is Chief Financial Officer of Lumos Pharma. She brings over ten years of experience and accounting expertise in overseeing financial operations, including over five years of public company senior management experience in biotechnology. Prior to the merger with Lumos Pharma, she held various senior roles of increasing responsibility in NewLink’s finance department, including...Read More

Aaron Schuchart

Aaron Schuchart is Chief Business Officer of Lumos Pharma.  Mr. Schuchart has over twenty years of experience in key leadership roles for both large multinationals and small biotech companies, including Amgen, Novartis Diagnostics/Grifols, and Coherus Biosciences. Recently, as Chief Business Officer of Aeglea BioTherapeutics, Mr. Schuchart led the Business Development, Commercial Planning, and Intellectual Property...Read More